Life Sciences Tools and Services
Company Overview of WuXi AppTec, Inc.
WuXi AppTec, Inc. provides contract research and development outsourcing services for pharmaceutical, biotechnology, and medical device industries worldwide. The company offers pharmaceutical services, including discovery services in the areas of synthetic and medicinal chemistry, analytical chemistry, discovery biology, pharmacology, safety pharmacology, drug metabolism and pharmacokinetics, and bioanalysis; and development services, such as process research and development, research and commercial manufacturing, analytical development, and pharmaceutical development. It also offers biologics development, testing, and manufacturing services for mammalian-derived protein therapeutic, microbi...
2540 Executive Drive
St. Paul, MN 55120
Founded in 1982
Key Executives for WuXi AppTec, Inc.
Co-Founder, Chairman of the Board, Chief Executive Officer and Member of Strategy Committee
Co-Founder, Senior Vice President of Operations, Head of Domestic Marketing and Director
Co-Founder, Executive Vice President and Director
Chief Financial Officer and Chief Operating Officer
Senior Vice President of Operations, Head of Corporate Human Resources and Director
Compensation as of Fiscal Year 2015.
WuXi AppTec, Inc. Key Developments
WuXi AppTec, Inc. Presents at Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa, Oct-07-2015 01:15 PM
Oct 2 15
WuXi AppTec, Inc. Presents at Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa, Oct-07-2015 01:15 PM. Venue: Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037, United States. Speakers: Alan Moore, Vice President of Testing and Cell Services.
REGENXBIO Inc Enters into Strategic Manufacturing Collaboration with WuXi AppTec, Inc
Jun 11 15
REGENXBIO Inc. announced that it has entered into an exclusive strategic manufacturing collaboration with WuXi AppTec, Inc. Through this collaboration, REGENXBIO plans to establish efficient, scalable manufacturing processes within current Good Manufacturing Practice guidelines for the production of adeno-associated virus gene therapy treatments incorporating REGENXBIO's NAV Technology. Under the terms of the agreement, REGENXBIO and WuXi will establish a proprietary production process for NAV Technology treatments designed to enable the rapid advancement of REGENXBIO's and licensees' therapeutic programs from clinical trials through commercialization in WuXi's 145,000 square-foot cGMP facility currently under construction in Philadelphia. This facility is specially designed to accommodate gene therapy products that contain viral vectors such as REGENXBIO's NAV Technology platform. The partnership will combine REGENXBIO's expertise in AAV process development with WuXi's commercial manufacturing proficiency and established infrastructure. As part of the collaboration, REGENXBIO has already initiated with WuXi the production of material to be used in planned clinical trials. This unique collaboration enables WuXi to work closely with REGENXBIO to provide an integrated solution to its gene therapy needs.
WuXi AppTec, Inc. Presents at ChinaBio Partnering Forum 2015, Apr-15-2015 11:00 AM
Apr 13 15
WuXi AppTec, Inc. Presents at ChinaBio Partnering Forum 2015, Apr-15-2015 11:00 AM. Venue: Kerry Hotel, Pudong, Shanghai, China. Speakers: Steve Yang, Executive VP and COO.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|